IRADIMED Yönetim

Yönetim kriter kontrolleri 4/4

IRADIMED CEO'su Roger Susi, Jan2004 tarihinde atandı, in görev süresi 20.83 yıldır. in toplam yıllık tazminatı $ 642.57K olup, şirket hissesi ve opsiyonları dahil olmak üzere 47.9% maaş ve 52.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 36.2% ine doğrudan sahiptir ve bu hisseler $ 244.22M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 8.4 yıldır.

Anahtar bilgiler

Roger Susi

İcra Kurulu Başkanı

US$642.6k

Toplam tazminat

CEO maaş yüzdesi	47.9%
CEO görev süresi	20.8yrs
CEO sahipliği	36.2%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	8.4yrs

Son yönetim güncellemeleri

Recent updates

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Aug 08

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

IRadimed: Reduce Equity Beta With Upside Capture

Jul 18

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Jul 13

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Feb 05

Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Jan 12

CEO Tazminat Analizi

Roger Susi'un ücretlendirmesi IRADIMED'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$19m
Jun 30 2024	n/a	n/a	US$19m
Mar 31 2024	n/a	n/a	US$18m
Dec 31 2023	US$643k	US$308k	US$17m
Sep 30 2023	n/a	n/a	US$16m
Jun 30 2023	n/a	n/a	US$15m
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$586k	US$290k	US$13m
Sep 30 2022	n/a	n/a	US$13m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$10m
Dec 31 2021	US$615k	US$308k	US$9m
Sep 30 2021	n/a	n/a	US$6m
Jun 30 2021	n/a	n/a	US$5m
Mar 31 2021	n/a	n/a	US$987k
Dec 31 2020	US$435k	US$290k	US$1m
Sep 30 2020	n/a	n/a	US$4m
Jun 30 2020	n/a	n/a	US$5m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	US$488k	US$288k	US$10m
Sep 30 2019	n/a	n/a	US$8m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	n/a	n/a	US$7m
Dec 31 2018	US$495k	US$279k	US$6m
Sep 30 2018	n/a	n/a	US$5m
Jun 30 2018	n/a	n/a	US$3m
Mar 31 2018	n/a	n/a	US$2m
Dec 31 2017	US$474k	US$268k	US$500k

Tazminat ve Piyasa: Roger 'nin toplam tazminatı ($USD 642.57K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 3.17M ).

Tazminat ve Kazançlar: Roger 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Roger Susi (71 yo)

20.8yrs

Görev süresi

US$642,566

Tazminat

Mr. Roger E. Susi serves as President and Chief Executive Officer of IRadimed Corporation since May 28, 2020. He founded IRadimed Corporation in 2004 and has been its Chairman of the Board since June 10, 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Roger Susi	Founder	20.8yrs	US$642.57k	36.2% $ 244.2m
John Glenn	CFO & Corporate Secretary	2.4yrs	US$1.27m	0.054% $ 366.4k
Randy Waddell	Vice President of Worldwide Sales & Marketing	3.3yrs	US$597.28k	0.047% $ 318.3k
Chris Williamson	Executive Vice President of Continuous Improvement & Information Technology	2.4yrs	Veri yok	Veri yok
Matt Garner	Controller	4.8yrs	Veri yok	Veri yok
Steve Kachelmeyer	Vice President of Regulatory Affairs & Quality Assurance	no data	US$425.08k	0.042% $ 280.8k
Lynn Neuhardt	Vice President of Research & Development	no data	US$442.20k	0.050% $ 338.0k

3.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: IRMD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Roger Susi	Founder	8.4yrs	US$642.57k	36.2% $ 244.2m
James Hawkins	Director	5.4yrs	US$159.36k	0.31% $ 2.1m
Anthony Vuoto	Independent Director	8.7yrs	US$167.48k	0.11% $ 757.7k
Monty Allen	Independent Director	10.8yrs	US$169.98k	0.14% $ 961.0k
Hilda Scharen-Guivel	Independent Director	2.1yrs	US$153.11k	0.028% $ 188.1k

8.4yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IRMD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.4 yıldır).

IRADIMED Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Director recently sold US$84k worth of stock

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Independent Director recently sold US$122k worth of stock

Founder notifies of intention to sell stock

Recent updates

Iradimed Corporation Revises Earnings Guidance for the Year 2024

IRADIMED CORPORATION to Report Q3, 2024 Results on Oct 31, 2024

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

IRADIMED CORPORATION Declares A Regular Quarterly Cash Dividend, Payable on August 30, 2024

IRADIMED CORPORATION to Report Q2, 2024 Results on Aug 01, 2024

Independent Director recently sold US$84k worth of stock

Upcoming dividend of US$0.15 per share

IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend, Payable on May 30, 2024

Now 25% overvalued

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Now 21% overvalued

Now 21% overvalued after recent price rise

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

Director notifies of intention to sell stock

IRadimed Corporation Approves Initiation of Regular Quarterly Dividend, Payable on January 12, 2024

Director notifies of intention to sell stock

Independent Director recently sold US$122k worth of stock

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

Founder notifies of intention to sell stock

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Price target increased by 9.5% to US$57.50

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Independent Director recently sold US$128k worth of stock

Price target increased by 14% to US$52.50

IRadimed Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023

IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023

Investor sentiment improves as stock rises 16%

Price target increased to US$46.00

IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023

Independent Director exercised options to buy US$87k worth of stock.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022

IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

IRadimed Corporation Announces Board Changes

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Investor sentiment deteriorated over the past week

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Independent Director recently sold US$116k worth of stock

Insufficient new directors

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022

IRadimed: Reduce Equity Beta With Upside Capture

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Insufficient new directors

IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022

Price target decreased to US$40.00

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$53.00